WD repeat domain 5 (WDR5) inhibitors: a patent review (2016-present)
JA Coker, SR Stauffer - Expert Opinion on Therapeutic Patents, 2025 - Taylor & Francis
Introduction WDR5 is an epigenetic scaffolding protein that has attracted significant interest
as an anti-cancer drug target, especially in MLL-rearranged leukemias. The most druggable …
as an anti-cancer drug target, especially in MLL-rearranged leukemias. The most druggable …